About the Oxford Brain Health Clinical Trials Unit
The substantial growth in mental health and dementia-related research activity and clinical research infrastructure in Oxford has resulted in increasing numbers of associated clinical trials. From its inception in 2019 the Oxford Brain Health Clinical Trials Unit (OBHCTU) has played an important role in supporting mental health and dementia focused trials.
As the only mental health specific Clinical Trials Unit (CTU) in the UK, our mission is to conduct high quality and patient-centric research. In doing so, we aim to achieve an international reputation for being a research-led CTU that focuses on a variety of research projects, but predominantly in the mental health and dementia fields. As dementia and mental health trials are becoming more biomarker and technology focused, a CTU with specific mental health and dementia experience will significantly benefit the conduct and delivery of such trials.
Our aspiration is that we will be able to influence continuous improvement within clinical services by way of high-quality research and as per the NHS constitution, every patient should have the opportunity to be part of a research study. To do this, we work closely with the NIHR Oxford Health Biomedical Research Centre, NIHR Oxford Cognitive Health Clinical Research Facility, Oxford Health NHS Foundation Trust and Oxford University Hospitals NHS Foundation Trust as well as other academic, NHS and industry partners.
Oxford Brain Health Clinical Trials Unit (OBHCTU) was established in 2019 to support the delivery of high quality clinical trials in psychiatry and cognitive sciences. In doing so, the trials unit has become the only UK CTU dedicated to mental health and in 2019 we obtained ISO 9001;2015 for our Quality Management Systems and Royal Charter accreditation. Research in mental health and dementia can have specific challenges, particularly in terms of recruitment, the running of studies and interpreting research data, and we aim to support researchers in navigating this complex field.
We have a developing portfolio and particular expertise in medical device trials, and are able to provide training in these areas. We are also developing a growing portfolio of early phase interventional trials, especially in the field of cognitive impairment and plan to attain ISO registration for medical devices and UKCRC registration in 2021.
Our vision is to support, collaborate and partner with researchers to mitigate the problems running and interpreting such complex mental health clinical trials, and so ultimately allowing more translation into clinical services.